Assetmark, Inc Novo Cure LTD Transaction History

Assetmark, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	BUY	$16.15 - $42.35 $31,298 - $82,074	1,938 Added 37.07%	7,166 $115,000
Q2 2023 Aug 11, 2023	BUY	$40.29 - $82.51 $23,609 - $48,350	586 Added 12.62%	5,228 $216,000
Q1 2023 May 05, 2023	SELL	$56.44 - $118.81 $103,962 - $218,848	-1,842 Reduced 28.41%	4,642 $279,000
Q4 2022 Feb 10, 2023	BUY	$63.98 - $85.37 $51,311 - $68,466	802 Added 14.11%	6,484 $475,000
Q3 2022 Nov 01, 2022	BUY	$67.99 - $89.57 $88,047 - $115,993	1,295 Added 29.52%	5,682 $432,000
Q2 2022 Aug 03, 2022	BUY	$56.6 - $89.9 $51,902 - $82,438	917 Added 26.43%	4,387 $305,000
Q1 2022 May 13, 2022	BUY	$60.15 - $84.52 $108,270 - $152,136	1,800 Added 107.78%	3,470 $287,000
Q4 2021 Feb 14, 2022	BUY	$75.08 - $121.99 $120,578 - $195,915	1,606 Added 2509.38%	1,670 $125,000
Q3 2021 Nov 12, 2021	BUY	$116.17 - $194.55 $7,434 - $12,451	64 New	64 $7,000
Q1 2020 May 12, 2020	SELL	$57.05 - $95.75 $798 - $1,340	-14 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$61.86 - $97.8 $866 - $1,369	14 New	14 $1,000

262

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $3.04B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

Stay updated on Assetmark, Inc with notifications on news.